Qnexa May Get Staged Launch After No Vote From Advisory Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
Safety concerns and a large market potential for Vivus's obesity drug combine to produce an advisory panel recommendation that leaves FDA "a little surprised."
You may also be interested in...
Qnexa’s Second Advisory Committee Review: Smaller Indication, Still Big Safety Questions
Vivus’ weight loss drug Qnexa (phentermine/topiramate) will go before the Endocrinologic and Metabolic Drugs Advisory Committee again on Feb. 22 for an indication that excludes women of childbearing age. And despite additional safety data, cardiovascular concerns look to remain a major issue for the resubmitted application.
Vivus Resubmits Qnexa, But Limits Its Market Opportunity
The biotech once again submits its application to FDA for its obesity drug, but the upside potential is drastically cut.
Vivus Resubmits Qnexa, But Limits Its Market Opportunity
The biotech once again submits its application to FDA for its obesity drug, but the upside potential is drastically cut.